{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:22:44Z","timestamp":1789662164568,"version":"4.0.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"16","license":[{"start":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T00:00:00Z","timestamp":1635379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T00:00:00Z","timestamp":1635379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s40265-021-01613-y","type":"journal-article","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T10:03:03Z","timestamp":1635415383000},"page":"1905-1913","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Avatrombopag: A Review in Thrombocytopenia"],"prefix":"10.1007","volume":"81","author":[{"given":"Anthony","family":"Markham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,28]]},"reference":[{"key":"1613_CR1","unstructured":"Kuter D. MSD manual: professional version; overview of platelet disorders. 2020. https:\/\/www.msdmanuals.com\/professional\/hematology-and-oncology\/thrombocytopenia-and-platelet-dysfunction\/overview-of-platelet-disorders. Accessed 17 Sep 2021."},{"issue":"23","key":"1613_CR2","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","volume":"3","author":"C Neunert","year":"2019","unstructured":"Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829\u201366.","journal-title":"Blood Adv"},{"issue":"8","key":"1613_CR3","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1111\/j.1365-2036.2006.02889.x","volume":"23","author":"EG Giannini","year":"2006","unstructured":"Giannini EG. Review article: thrombocytopenia in chronic liver disease and pharmacologic treatment options. Aliment Pharmacol Ther. 2006;23(8):1055\u201365.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"1613_CR4","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.cgh.2009.02.021","volume":"7","author":"AA Qamar","year":"2009","unstructured":"Qamar AA, Grace ND, Groszmann RJ, et al. Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis. Clin Gastroenterol Hepatol. 2009;7(6):689\u201395.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"22","key":"1613_CR5","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","volume":"3","author":"D Provan","year":"2019","unstructured":"Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780\u2013817.","journal-title":"Blood Adv"},{"key":"1613_CR6","doi-asserted-by":"publisher","first-page":"5421632","DOI":"10.1155\/2020\/5421632","volume":"2020","author":"F Poordad","year":"2020","unstructured":"Poordad F, Terrault NA, Alkhouri N, et al. Avatrombopag, an alternate treatment option to reduce platelet transfusions in patients with thrombocytopenia and chronic liver disease-integrated analyses of 2 phase 3 studies. Int J Hepatol. 2020;2020:5421632.","journal-title":"Int J Hepatol."},{"key":"1613_CR7","unstructured":"Swedish Orphan Biovitrum. Doptelet\u00ae (avatrombopag): US prescribing information. 2020. https:\/\/doptelet.com\/themes\/pdf\/prescribing-information.pdf. Accessed 17 Sep 2021."},{"key":"1613_CR8","unstructured":"Swedish Orphan Biovitrum. Doptelet\u00ae (avatrombopag): EU summary of product characteristics. 2021. https:\/\/www.ema.europa.eu\/. Accessed 17 Sep 2021."},{"issue":"1","key":"1613_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s12185-013-1382-0","volume":"98","author":"DJ Kuter","year":"2013","unstructured":"Kuter DJ. The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol. 2013;98(1):10\u201323.","journal-title":"Int J Hematol"},{"issue":"4","key":"1613_CR10","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1600-0609.2008.01198.x","volume":"82","author":"M Fukushima-Shintani","year":"2009","unstructured":"Fukushima-Shintani M, Suzuki K, Iwatsuki Y, et al. AKR-501 (YM477) a novel orally-active thrombopoietin receptor agonist. Eur J Haematol. 2009;82(4):247\u201354.","journal-title":"Eur J Haematol"},{"issue":"10","key":"1613_CR11","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.exphem.2008.04.020","volume":"36","author":"M Fukushima-Shintani","year":"2008","unstructured":"Fukushima-Shintani M, Suzuki K, Iwatsuki Y, et al. AKR-501 (YM477) in combination with thrombopoietin enhances human megakaryocytopoiesis. Exp Hematol. 2008;36(10):1337\u201342.","journal-title":"Exp Hematol"},{"issue":"12","key":"1613_CR12","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1111\/jth.14295","volume":"16","author":"AD Michelson","year":"2018","unstructured":"Michelson AD, Smolensky Koganov E, Forde EE, et al. Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease. J Thromb Haemost. 2018;16(12):2515\u20139.","journal-title":"J Thromb Haemost"},{"issue":"12","key":"1613_CR13","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1002\/jcph.1267","volume":"58","author":"M Nomoto","year":"2018","unstructured":"Nomoto M, Ferry J, Hussein Z. Population pharmacokinetic\/pharmacodynamic analyses of avatrombopag in patients with chronic liver disease and optimal dose adjustment guide with concomitantly administered CYP3A and CYP2C9 inhibitors. J Clin Pharmacol. 2018;58(12):1629\u201338.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"1613_CR14","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1111\/bcp.13517","volume":"84","author":"M Nomoto","year":"2018","unstructured":"Nomoto M, Zamora CA, Schuck E, et al. Pharmacokinetic\/pharmacodynamic drug\u2013drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs. Br J Clin Pharmacol. 2018;84(5):952\u201360.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1613_CR15","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/bjh.15573","volume":"183","author":"W Jurczak","year":"2018","unstructured":"Jurczak W, Chojnowski K, Mayer J, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Br J Haematol. 2018;183(3):479\u201390.","journal-title":"Br J Haematol"},{"key":"1613_CR16","unstructured":"US National Institutes of Health. NCT01433978. 2021. https:\/\/clinicaltrials.gov\/. Accessed 17 Sep 2021."},{"issue":"Suppl. 1","key":"1613_CR17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1182\/blood-2020-142788","volume":"136","author":"MD Tarantino","year":"2020","unstructured":"Tarantino MD, Vredenburg M, Tian W, et al. Efficacy analyses from the immune thrombocytopenia (ITP) clinical development program for avatrombopag: comparisons with placebo and eltrombopag [abstract]. Blood. 2020;136(Suppl. 1):23\u20134.","journal-title":"Blood"},{"issue":"25","key":"1613_CR18","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1182\/blood-2013-07-514398","volume":"123","author":"JB Bussel","year":"2014","unstructured":"Bussel JB, Kuter DJ, Aledort LM, et al. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood. 2014;123(25):3887\u201394.","journal-title":"Blood"},{"key":"1613_CR19","doi-asserted-by":"publisher","DOI":"10.1080\/09537104.2021.1881952","author":"H Al-Samkari","year":"2021","unstructured":"Al-Samkari H, Nagalla S. Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension. Platelets. 2021. https:\/\/doi.org\/10.1080\/09537104.2021.1881952.","journal-title":"Platelets"},{"issue":"3","key":"1613_CR20","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1053\/j.gastro.2018.05.025","volume":"155","author":"N Terrault","year":"2018","unstructured":"Terrault N, Chen YC, Izumi N, et al. Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia. Gastroenterology. 2018;155(3):705\u201318.","journal-title":"Gastroenterology"},{"issue":"6","key":"1613_CR21","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.jhep.2014.07.007","volume":"61","author":"NA Terrault","year":"2014","unstructured":"Terrault NA, Hassanein T, Howell CD, et al. Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure. J Hepatol. 2014;61(6):1253\u20139.","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"1613_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1182\/blood-2020-141273","volume":"136","author":"CI Piatek","year":"2020","unstructured":"Piatek CI, Jamieson B, Vredenburg M. Characterization of thromboembolic events occurring during the avatrombopag immune thrombocytopenia (ITP) clinical development program [abstract no. 844]. Blood. 2020;136(Suppl 1):39.","journal-title":"Blood"},{"key":"1613_CR23","unstructured":"Swedish Orphan Biovitrum. EU summary of the risk management plan for Doptelet\u00ae. 2021. https:\/\/www.ema.europa.eu\/. Accessed 17 Sep 2021."},{"issue":"7","key":"1613_CR24","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/ajh.25125","volume":"93","author":"J Bussel","year":"2018","unstructured":"Bussel J, Arnold DM, Grossbard E, et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials. Am J Hematol. 2018;93(7):921\u201330.","journal-title":"Am J Hematol"},{"key":"1613_CR25","unstructured":"Instituto Grifols SA. Tavlesse\u00ae (fostamatinib): EU summary of product characteristics. 2020. https:\/\/www.ema.europa.eu\/. Accessed 17 Sep 2021."},{"key":"1613_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01752-4","author":"P Wojciechowski","year":"2021","unstructured":"Wojciechowski P, Wilson K, Nazir J, et al. Efficacy and safety of avatrombopag in patients with chronic immune thrombocytopenia: a systematic literature review and network meta-analysis. Adv Ther. 2021. https:\/\/doi.org\/10.1007\/s12325-021-01752-4.","journal-title":"Adv Ther"},{"key":"1613_CR27","unstructured":"Al-Samkari H, Jiang D, Gernsheimer T, et al. A multicenter U.S. study of avatrombopag switch therapy following prior eltrombopag or romiplostim [abstract no. EP1141]. In: European Hematology Association Virtual Congress. 2021."},{"key":"1613_CR28","unstructured":"US National Institutes of Health. NCT04638829. 2021. https:\/\/clinicaltrials.gov\/. Accessed 17 Sep 2021."},{"key":"1613_CR29","unstructured":"US National Institutes of Health. NCT04943042. 2021. https:\/\/clinicaltrials.gov\/. Accessed 17 Sep 2021."},{"key":"1613_CR30","unstructured":"Novartis Europharm Ltd. Revolade\u00ae (eltrombopag): EU summary of product characteristics. 2021. https:\/\/www.ema.europa.eu\/. Accessed 17 Sep 2021."},{"key":"1613_CR31","unstructured":"Amgen Europe B.V. Nplate\u00ae (romiplostim): EU summary of product characteristics. 2021. https:\/\/www.ema.europa.eu\/. Accessed 17 Sep 2021."},{"issue":"6","key":"1613_CR32","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.jhep.2008.03.009","volume":"48","author":"N Afdhal","year":"2008","unstructured":"Afdhal N, McHutchison J, Brown R, et al. Thrombocytopenia associated with chronic liver disease. J Hepatol. 2008;48(6):1000\u20137.","journal-title":"J Hepatol"},{"key":"1613_CR33","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3410\/M2-5","volume":"2","author":"N Blumberg","year":"2010","unstructured":"Blumberg N, Heal JM, Phillips GL. Platelet transfusions: trigger, dose, benefits, and risks. F1000 Med Rep. 2010;2:5.","journal-title":"F1000 Med Rep."},{"issue":"10","key":"1613_CR34","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.1182\/blood-2003-08-2724","volume":"105","author":"SJ Slichter","year":"2005","unstructured":"Slichter SJ, Davis K, Enright H, et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood. 2005;105(10):4106\u201314.","journal-title":"Blood"},{"key":"1613_CR35","unstructured":"UK National Institute for Health and Care Excellence. Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure. 2020. https:\/\/www.nice.org.uk\/guidance\/ta626. Accessed 17 Sep 2021."},{"issue":"10","key":"1613_CR36","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1155\/2014\/532191","volume":"28","author":"VG Gangireddy","year":"2014","unstructured":"Gangireddy VG, Kanneganti PC, Sridhar S, et al. Management of thrombocytopenia in advanced liver disease. Can J Gastroenterol Hepatol. 2014;28(10):558\u201364.","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"5","key":"1613_CR37","doi-asserted-by":"publisher","first-page":"160","DOI":"10.4329\/wjr.v6.i5.160","volume":"6","author":"TA Hadduck","year":"2014","unstructured":"Hadduck TA, McWilliams JP. Partial splenic artery embolization in cirrhotic patients. World J Radiol. 2014;6(5):160\u20138.","journal-title":"World J Radiol."},{"issue":"3","key":"1613_CR38","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1002\/bjs.7367","volume":"98","author":"K Feng","year":"2011","unstructured":"Feng K, Ma K, Liu Q, et al. Randomized clinical trial of splenic radiofrequency ablation versus splenectomy for severe hypersplenism. Br J Surg. 2011;98(3):354\u201361.","journal-title":"Br J Surg"},{"issue":"5","key":"1613_CR39","first-page":"286","volume":"13","author":"OI Massoud","year":"2017","unstructured":"Massoud OI, Zein NN. The effect of transjugular intrahepatic portosystemic shunt on platelet counts in patients with liver cirrhosis. Gastroenterol Hepatol (N Y). 2017;13(5):286\u201391.","journal-title":"Gastroenterol Hepatol (N Y)."},{"key":"1613_CR40","unstructured":"Satapathy S, Jamieson B. Real-world use of avatrombopag in patients with severe thrombocytopenia associated with chronic liver disease undergoing a procedure [abstract no. PO-2634]. J Hepatol. 2021;75(Suppl 2):1."},{"key":"1613_CR41","doi-asserted-by":"crossref","unstructured":"Wojciechowski P, Wilson K, Pochopien M, et al. Comparative efficacy and safety of avatrombopag versus lusutrombopag in patients with chronic LIVER disease and severe thrombocytopenia undergoing invasive procedures: a systematic literature review and network meta-analysis [abstract no. PDB34]. In: International Society for Pharmacoeconomics and Outcomes. 2021.","DOI":"10.1016\/j.jval.2021.04.431"},{"key":"1613_CR42","doi-asserted-by":"publisher","first-page":"515","DOI":"10.2147\/CEOR.S262772","volume":"12","author":"D Mladsi","year":"2020","unstructured":"Mladsi D, Barnett C, Aggarwal K, et al. Cost-effectiveness of avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease. Clinicoecon Outcomes Res. 2020;12:515\u201326.","journal-title":"Clinicoecon Outcomes Res."}],"updated-by":[{"DOI":"10.1007\/s40265-021-01651-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01613-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-021-01613-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01613-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T15:13:50Z","timestamp":1638198830000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-021-01613-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,28]]},"references-count":42,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["1613"],"URL":"https:\/\/doi.org\/10.1007\/s40265-021-01613-y","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40265-021-01651-6","asserted-by":"object"}]},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,28]]},"assertion":[{"value":"19 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2021","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40265-021-01651-6","URL":"https:\/\/doi.org\/10.1007\/s40265-021-01651-6","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"A. Markham is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}